Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2
years. Dosage was adjusted according to side effects. Neurological assessment including the
determination of the Expanded Disability Status Scale (EDSS) score and ophthalmologic
evaluations were performed every 3 months and during relapses. Flow cytometric analysis,
brain and spinal cord MRI was performed at baseline, 6, 12, 18, and 24 months.